Metagenomi, Inc.

Equities

MGX

US59102M1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
6.38 USD -0.16% Intraday chart for Metagenomi, Inc. -2.60% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target MT
North American Morning Briefing : Apple, Amgen -2- DJ
Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating MT
JPMorgan Downgrades Metagenomi to Neutral, Price Target at $6 MT
Metagenomi, Inc. and Modernatx, Inc. Terminate the Strategic Collaboration and License Agreement CI
Metagenomi 2023 Loss Widens, Revenue Rises MT
Metagenomi, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Metagenomi, Inc.(NasdaqGS:MGX) added to S&P TMI Index CI
TD Cowen Initiates Metagenomi With Outperform Rating MT
Jefferies Starts Metagenomi With Buy Rating, $23 Price Target MT
BMO Capital Starts Metagenomi With Outperform Rating, $22 Price Target MT
Wells Fargo Starts Metagenomi With Overweight Rating, $25 Price Target MT
JPMorgan Starts Metagenomi With Overweight Rating, $16 Price Target MT
Chardan Starts Metagenomi With Buy Rating, Price Target is $21 MT
Metagenomi Closes $93.8 Million IPO MT
Metagenomi, Inc.(NasdaqGS:MGX) added to NASDAQ Composite Index CI
Metagenomi, Inc. has completed an IPO in the amount of $93.75 million. CI
Metagenomi, Inc. has filed an IPO in the amount of $100 million. CI
Chart Metagenomi, Inc.
More charts
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.38 USD
Average target price
16.83 USD
Spread / Average Target
+163.85%
Consensus
  1. Stock Market
  2. Equities
  3. MGX Stock
  4. News Metagenomi, Inc.
  5. BMO Capital Starts Metagenomi With Outperform Rating, $22 Price Target